| Autor: |
Luongo C; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy., Porcelli T; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy., Sessa F; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy., De Stefano MA; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy., Scavuzzo F; Department of Endocrinology, Aziena Ospedaliera di Rilievo Nazionale A. Cardarelli, 80131 Naples, Italy., Damiano V; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy., Klain M; Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy., Bellevicine C; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy., Matano E; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy., Troncone G; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy., Schlumberger M; Department of Endocrine Oncology, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France., Salvatore D; Department of Public Health, University of Naples Federico II, 80131 Naples, Italy. |
| Abstrakt: |
Anaplastic thyroid cancer (ATC) is a rare but aggressive thyroid cancer, responsible for about 50% of all thyroid cancer-related deaths. During the last two decades, the development of a multimodal personalized approach resulted in an increased survival. Here, we present an unusual case of a 54-year old woman with a paucicellular metastatic ATC, a rare variant of ATC, who was treated with a combination of surgery, radiation therapy and cytotoxic chemotherapy. More than two years later, when the disease was rapidly growing, a combination of lenvatinib and pembrolizumab induced a partial tumor response of lung metastasis that persisted over 18 months. Paucicellular ATC may initially show a less aggressive behavior compared to other histological ATC variants. However, over the time, its clinical course can rapidly progress like common ATC. The combination of lenvatinib and pembrolizumab was effective as a salvage therapy for a long period of time. |
